Measuring Symptom Relief After Radiofrequency Ablation of the Thyroid
Launched by MAYO CLINIC · Aug 12, 2022
Trial Information
Current as of September 11, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This is an observational study at Mayo Clinic that follows about 300 adults who are getting thyroid radiofrequency ablation (RFA) to treat a symptomatic thyroid nodule. The researchers want to see how these symptoms change after the procedure over time, using a simple 6-question score that ranges from 0 (none) to 2 (severe). They will check symptoms before treatment and then at 1, 3, 6, 12, 18, and 24 months after RFA, to understand how much relief people have.
Eligibility is for adults 18 and older who are undergoing RFA for a symptomatic thyroid nodule, and who are willing to participate (those who decline cannot join). The study is enrolling by invitation and is not testing a drug or device. It’s an observational, prospective cohort run by Mayo Clinic Rochester (NCT05501041) led by Dr. Thomas Atwell. Results aren’t available yet, and the study plans to collect data through 2028.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - Undergoing Radiofrequency Ablation (RFA) for symptomatic thyroid nodule(s).
- Exclusion Criteria:
- • - Decline to participate in research.
About Mayo Clinic
Mayo Clinic is a renowned nonprofit medical practice and research institution dedicated to providing comprehensive healthcare and advancing medical knowledge through innovative research and education. With a commitment to patient-centered care, Mayo Clinic conducts numerous clinical trials aimed at exploring new therapies and improving treatment outcomes across various disciplines. Leveraging a multidisciplinary approach, the institution collaborates with leading experts and cutting-edge technology to ensure rigorous scientific standards and ethical practices in all its research endeavors. Through its trials, Mayo Clinic seeks to translate breakthroughs in science into tangible benefits for patients, fostering advancements in medicine that enhance health and quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Patients applied
Trial Officials
Thomas Atwell, MD
Principal Investigator
Mayo Clinic
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials